¡DESCUBRE QUÉ VALOR APORTA CREATIO A LA SOCIEDAD!
Read more
15 April, 2024
DR. JORDI ABANTE, POSTDOCTORAL RESEARCHER AT CREATIO, OBTAINS A GRANT FROM THE JUNIOR LEADER FELLOWSHIPS - INCOMING PROGRAM OF "LA CAIXA" FOUNDATION
Read more
28 March, 2024
Read more
21 March, 2024
THE SOLUBLE MUTANT HUNTINGTIN PROTEIN IS ONE OF THE RESPONSIBLE FOR THE SPREADING AND DEVELOPMENT OF HUNTINGTON'S DISEASE IN THE EARLY STAGES
Read more
8 August, 2023
THE UNIVERSITY OF BARCELONA PROMOTES INNOVATION AND TRANSFER AND ACQUIRES THE EXPERIMENTAL TOXICOLOGY PLATFORM UTOX OF THE BARCELONA SCIENCE PARK
Read more
22 June, 2023
AN OPTIMIZED HYALURONIC ACID- BASED BIOINK COMPATIBLE WITH NEURAL NETWORK FORMATION IS DEVELOPED BY ASCTN-ITN PROJECT
Read more
24 April, 2023
THE SPANISH ADVANCED THERAPY NETWORK HAS RELEASED POSITION PAPER ABOUT THE ROLE OF HOSPITAL EXEMPTION IN EUROPE
Read more
30 March, 2023
UNISTEM DAY 2023, HOSTED AT THE UNIVERSITY OF BARCELONA, APPROACHED STEM CELLS AND REGENERATIVE MEDICINE RESEARCH TO MORE THAN 100 HIGH SCHOOL STUDENTS
Read more
16 March, 2023
QREM REGENERATIVE TECHNOLOGY TOGETHER WITH CREATIO UB WILL DEVELOP AN INNOVATIVE PROTOCOL TO ISOLATE IMMUNE SYSTEM CELLS
Read more
16 January, 2023
DR. JOSEP M. CANALS PARTICIPATES IN THE JOINT RESEARCH COUNCIL (JRC) REPORT ON ALTERNATIVE METHODS TO TEST IMMUNOGENECITY FOR THE EUROPEAN COMMISSION (EC)
Read more
17 November, 2022
4-DEEP BRAIN RECONSTRUCTION (4-DBR), AN INNOVATIVE EUROPEAN PROJECT FOR BRAIN REGENERATION TO TREAT NEURODEGENERATIVE DISORDERS, WAS LAUNCHED IN SEPTEMBER 2022
Read more
20 October, 2022
CREATIO HAS SUCCESSFULLY PASSED THE AUDIT AND RENEWS THE ISO 9001:2015 CERTIFICATION FOR 3 MORE YEARS
Read more
5 October, 2022
THE UNIVERSITY OF BARCELONA AND POIETIS ANNOUNCE THEIR PARTNERSHIP TO SET-UP A GMP-COMPLIANT BIOPRINTING FACILITY IN THE PRODUCTION AND VALIDATION CENTER FOR ADVANCED THERAPIES OF THE UNIVERSITY (CREATIO)
Read more
26 September, 2022
DR. JORDI ABANTE LLENAS, POSTDOCTORAL RESEARCH FELLOW AT STANFORD UNIVERSITY (UNITED STATES), WILL GIVE A CONFERENCE ON SEPTEMBER 23rd AT 3:00 P.M. IN THE SALA DOLORS ALEU I RIERA (ROOM 14) OF THE CAMPUS CLINIC (UNIVERSITY OF BARCELONA).
Read more
21 September, 2022
CREATIO’S PAPER DESCRIBING A SIGNIFICANT REDUCTION OF GENOMIC INSTABILITY IN HUMAN STEM CELL LINES UNDER QUALITY MANAGEMENT SYSTEM (QMS) CONDITIONS PUBLISHED AT CELLS
Read more
4 July, 2022
CREATIO PARTICIPATES IN THE GUIDELINES TO BRING RESEARCH CLOSER TO THE CLINIC FOR HUNTINGTON PATIENTS
Read more
13 April, 2022
ALTERATION OF THE CD200-CD200R1 IN HUNTINGTON’S DISEASE IS DESCRIBED FOR THE FIRST TIME
Read more
2 April, 2022
CREATIO RECEIVES FUNDING TO ACQUIRE A 4D BIOPRINTER
Read more
16 March, 2022
NEURONAL REPROGRAMMING TO SLOW HUNTINGTON'S DISEASE
Read more
21 July, 2021
A NEW INTERNATIONAL CONSORTIUM TO PROMOTE STEM CELL-BASED THERAPY FOR HUNTINGTON'S DISEASE
Read more
8 April, 2021
CREATIO PARTICIPA EN LA PRODUCCIÓN DE LA TERAPIA AVANZADA CAR-T ARI-0001
Read more
5 March, 2021
CREATIO PUBLISHES A GUIDELINE FOR CLINICAL-GRADE HEK293T CELL BANKING FOR LENTIVIRAL PARTICLE PRODUCTION
Read more
11 December, 2020
CREATIO WILL PARTICIPATE IN A NEW EUROPEAN PROJECT, FET-OPEN, LED AT THE UB BY RESEARCHERS JORDI SORIANO AND DANIEL TORNERO
Read more
12 November, 2020
CREATIO AND DATASCIENCE COLLABORATE TO DEVELOP AN IN SILICO MODEL FOR DRUG SCREENING IN NEURODEGENERATIVE DISEASES
Read more
2 November, 2020
CREATIO PUBLISHES THE FIRST SCIENTIFIC REVIEW ON THE IMPACT OF THE IMMUNE RESPONSE IN PARKINSON'S AND HUNTINGTON’S PATIENTS TREATED WITH CELL THERAPY, EVALUATING CLINICAL TRIALS CONDUCTED IN THE PAST FOUR DECADES
Read more
9 October, 2020
CREATIO CONTINUES TO ADVANCE IN THE FIELD OF NEUROIMMUNOLOGY TO ELUCIDATE THE PATHOPHYSIOLOGY OF HUNTINGTON’S DISEASE
Read more
18 June, 2020
CREATIO EXPANDS RESEARCH INITIATIVES TO SCHIZOPHRENIA AND CONTRIBUTES TO THE CHARACTERIZATION OF A NEW MOLECULAR AXIS RELEVANT FOR THE PATHOPHYSIOLOGY OF THE DISEASE
Read more
15 May, 2020
CREATIO EXPANDE SUS HORIZONTES DE INVESTIGACIÓN HACIA OTRAS ENFERMEDADES NEURODEGENERATIVAS; LA ESQUIZOFRENIA Y CONTRIBUYE A LA CARACTERIZACIÓN DE UN NUEVO EJE MOLECULAR RELEVANTE PARA LA FISIOPATOLOGÍA DE LA ENFERMEDAD
Read more
15 May, 2020
THE FIRST CREATIO’S GIVIMP-COMPATIBLE PROTOCOL TO DIFFERENTIATE PLURIPOTENT STEM CELLS INTO FUNCTIONAL NEURONS
Read more
1 May, 2020
LAUNCH OF THE NEW AVANTDRUG WEBSITE
Read more
29 April, 2020
CREATIO CONTRIBUTES TO THE SUCCESSFUL PRODUCTION OF CAR-T CELLS USED IN CLINICAL TRIAL AGAINST BLOOD CANCER
Read more
26 March, 2020
NEUROTOXICOLOGY AND DRUG SCREENING PLATFORM - AVANTDRUG
Read more
7 May, 2019
A PROGRAM GIVES 3.8 MILLION EUROS TO TRAIN YOUNG RESEARCHERS IN CELLULAR THERAPIES APPLIED TO NEURONAL DISEASES
Read more
17 October, 2018
INTERVIEW WITH JOSEP M CANALS FOR ADVANCE(CAT)
Read more
18 May, 2018
THE WORLD'S LARGEST FOUNDATION IN THE SEARCH FOR A CURE FOR NEURODEGENERATIVE HUNTINGTON'S DISEASE, CHDI, HAS SHOWN CONTINUED TRUST IN CREATIO FOR THE PAST FEW YEARS.
Read more
10 April, 2018
NEUROSCIENCE 2017 CONGRESS
Read more
11 November, 2017
RESULTS BIOJAPAN 2017
Read more
23 October, 2017
BIOJAPAN 2017 - ASIA'S PREMIER PARTNERING EVENT FOR THE GLOBAL BIOTECHNOLOGY INDUSTRY
Read more
11 October, 2017
ADVANCE(CAT) CONSORTIUM IS LAUNCH TO PROMOTE ADVANCED THERAPIES IN CATALONIA
Read more
8 March, 2017
AN INTERNATIONAL STUDY WITH THE PARTICIPATION OF THE UB SHOWS THAT HUNTINGTON'S DISEASE ALTERES NEURONS SINCE ITS DEVELOPMENT
Read more
8 March, 2017